Merck & Co., Inc. (NYSE:MRK), the second-largest US drug maker, has announced an agreement with the Medicines Patent Pool (MPP) for its HIV drug, raltegravir, in its efforts to expedite the process of developing low-priced pediatric formulations for developing countries.
Merck & Co., Inc. (NYSE:MRK) announced Monday that it has entered into a multi-year collaboration agreement with NGM Biopharmaceuticals Inc., a privately held biotechnology company, to research, develop, as well as commercialize innovative biologic therapies ranging across a wide array of therapeutics.
Editor’s Note: Richard J. Sandler is a partner at Davis Polk & Wardwell LLP and co-head of the firm’s global corporate governance group. This post is based on a Davis Polk client memorandum.
Amid the recent uptick in U.S. IPO transactions to levels not seen since the heady days of 1999 and 2000, Davis Polk’s pipeline of deals remains robust, leading us to believe that strength in the U.S.
Editor's Note: The following post comes to us from Benjamin Hermalin, Professor of Finance at the University of California, Berkeley; and Michael Weisbach, Professor of Finance at Ohio State University.
The central focus of research in corporate governance has historically been on the problems of controlling managers’ actions.
Editor’s Note: Andrew R. Brownstein is a partner in the Corporate Department at Wachtell, Lipton, Rosen & Katz. This post is based on a Wachtell Lipton firm memorandum by Mr. Brownstein, Adam O. Emmerich, David A. Katz, Trevor S.
Editor's Note: The following post comes to us from Lili Dai of the College of Business and Economics at Australian National University; Jerry Parwada and Bohui Zhang, both of the Finance Area at UNSW Australia.
That the medi
Merck & Co., Inc. (NYSE:MRK) ended up paying $8.4 billion to acquire Cubist Pharmaceuticals Inc (NASDAQ:CBST), a 37% premium over Cubist’s closing stock price of $74.36 Friday; however, by Monday morning, this amount looked at least $2 billion too high as Cubist lost a key patent-infringement case pertaining to its blockbuster drug, Cubicin.
TORONTO — The lengthy battle by Bre-X investors to recover billions in Canada’s largest mining fraud appears to be over in what one of the original plaintiff lawyers in the case called a “sad day” for accountability in Canada.
Under a settlement approved Thursday by the Alberta Court of Queens Bench, the remaining class-action suits were dismissed against the main defendants in the case, the estate of Bre-X’s late founder and CEO, David Walsh, and chief geologist John Felderhof.
Chemistfrog submits:Ariad Pharmaceuticals (NASDAQ: ARIA) captured Merck’s (NYSE: MRK) attention enough with its cancer drug, ridaforolimus, in July 2007 to forge a partnership to help Ariad through several clinical trials for multiple cancer indications.